abstract: There are clones of @entity2 cells which are different from normal myeloid cells in that they have become independent of @entity1 for cell viability and growth. The ability of these clones to bind three types of hematopoietic growth factors (MGI-1GM = @entity3 , @entity1 = @entity1 and MGI-1M = @entity5 = @entity5 ) was measured using the method of quantitative absorption at 1 degree C and low pH elution of cell-bound biological activity. Results of binding to normal myeloid and lymphoid cells were similar to those obtained by radioreceptor assays. The results indicate that the number of receptors on different clones of these leukemic cells varied from 0 to 1,300 per cell. The receptors have a high binding affinity. Receptors for different growth factors can be independently expressed in different clones. There was no relationship between expression of receptors for these growth factors and the phenotype of the leukemic cells regarding their ability to be induced to differentiate. The number of receptors on the leukemic cells was lower than on normal mature macrophages. Myeloid leukemic cells induced to differentiate by normal myeloid cell differentiation factor MGI-2 (= DF), or by low doses of @entity4 or @entity0 , showed an up-regulation of the number of MGI-1GM and @entity1 receptors. Induction of differentiation of leukemic cells by MGI-2 also induced production and secretion of the growth factor MGI-1GM, and this induced MGI-1GM saturated the up-regulated MGI-1GM receptors. It is suggested that up-regulation of these receptors during differentiation is required for the functioning of differentiated cells.

title: Regulation of cell surface receptors for different hematopoietic growth factors on XXXX cells.

answer: @entity2


abstract: PURPOSE: An unusually high incidence of @entity5 was observed during a phase I/II trial of high-dose intravenous @entity3 (CsA) therapy to @entity1 multidrug resistance (MDR). Five of 21 @entity0 experienced severe @entity5 shortly after initiation of the first or second CsA infusion. We hypothesized that improper dissolution of the vehicle Cremophor EL may have been a cause for these @entity5 . METHODS: All nurses who had administered intravenous @entity4 were interviewed regarding their technique of preparing the infusion and the occurrence of an anaphylactoid reaction. The responses were statistically analyzed. The effect of various mixing techniques on the distribution of Cremophor EL in the infusion was experimentally evaluated. Different mixing techniques were used to assess their effect on the distribution of Cremophor EL in the solution. RESULTS: Analysis of the preparation techniques of the CsA infusion showed significant correlation between suboptimal mixing of CsA by nurses and the occurrence of @entity5 (P = .02). Experimental simulation showed that suboptimal mixing results in an uneven distribution of Cremophor EL, which subsequently sinks to the bottom of the vial. CONCLUSION: Improper mixing of high-dose CsA infusions causes nonsolubilized Cremophor EL to sink to the outflow area of the bottle. An initial bolus infusion of highly concentrated Cremophor EL may produce an anaphylactoid-like response. This mechanism of @entity2 is important to recognize, because it is easily preventable by proper preparation of the infusion, thus reducing the incidence of potentially life-threatening @entity5 .

title: Anaphylactoid reactions in @entity0 receiving high-dose intravenous XXXX for reversal of @entity1 resistance: the causative role of improper dissolution of Cremophor EL.

answer: @entity3


abstract: PURPOSE: An unusually high incidence of @entity5 was observed during a phase I/II trial of high-dose intravenous @entity3 (CsA) therapy to @entity1 multidrug resistance (MDR). Five of 21 @entity0 experienced severe @entity5 shortly after initiation of the first or second CsA infusion. We hypothesized that improper dissolution of the vehicle Cremophor EL may have been a cause for these @entity5 . METHODS: All nurses who had administered intravenous @entity4 were interviewed regarding their technique of preparing the infusion and the occurrence of an anaphylactoid reaction. The responses were statistically analyzed. The effect of various mixing techniques on the distribution of Cremophor EL in the infusion was experimentally evaluated. Different mixing techniques were used to assess their effect on the distribution of Cremophor EL in the solution. RESULTS: Analysis of the preparation techniques of the CsA infusion showed significant correlation between suboptimal mixing of CsA by nurses and the occurrence of @entity5 (P = .02). Experimental simulation showed that suboptimal mixing results in an uneven distribution of Cremophor EL, which subsequently sinks to the bottom of the vial. CONCLUSION: Improper mixing of high-dose CsA infusions causes nonsolubilized Cremophor EL to sink to the outflow area of the bottle. An initial bolus infusion of highly concentrated Cremophor EL may produce an anaphylactoid-like response. This mechanism of @entity2 is important to recognize, because it is easily preventable by proper preparation of the infusion, thus reducing the incidence of potentially life-threatening @entity5 .

title: Anaphylactoid reactions in @entity0 receiving high-dose intravenous @entity3 for reversal of XXXX resistance: the causative role of improper dissolution of Cremophor EL.

answer: @entity1


abstract: PURPOSE: An unusually high incidence of @entity5 was observed during a phase I/II trial of high-dose intravenous @entity3 (CsA) therapy to @entity1 multidrug resistance (MDR). Five of 21 @entity0 experienced severe @entity5 shortly after initiation of the first or second CsA infusion. We hypothesized that improper dissolution of the vehicle Cremophor EL may have been a cause for these @entity5 . METHODS: All nurses who had administered intravenous @entity4 were interviewed regarding their technique of preparing the infusion and the occurrence of an anaphylactoid reaction. The responses were statistically analyzed. The effect of various mixing techniques on the distribution of Cremophor EL in the infusion was experimentally evaluated. Different mixing techniques were used to assess their effect on the distribution of Cremophor EL in the solution. RESULTS: Analysis of the preparation techniques of the CsA infusion showed significant correlation between suboptimal mixing of CsA by nurses and the occurrence of @entity5 (P = .02). Experimental simulation showed that suboptimal mixing results in an uneven distribution of Cremophor EL, which subsequently sinks to the bottom of the vial. CONCLUSION: Improper mixing of high-dose CsA infusions causes nonsolubilized Cremophor EL to sink to the outflow area of the bottle. An initial bolus infusion of highly concentrated Cremophor EL may produce an anaphylactoid-like response. This mechanism of @entity2 is important to recognize, because it is easily preventable by proper preparation of the infusion, thus reducing the incidence of potentially life-threatening @entity5 .

title: Anaphylactoid reactions in XXXX receiving high-dose intravenous @entity3 for reversal of @entity1 resistance: the causative role of improper dissolution of Cremophor EL.

answer: @entity0


abstract: Loss of the ability of @entity3 . "phaseolicola" NPS3121 to elicit a hypersensitive response on @entity0 and other nonhost plants was associated with loss of pathogenicity on the susceptible host bean. Eight independent, prototrophic transposon Tn5 insertion mutants which had lost the ability to elicit a hypersensitive response on @entity0 plants were identified. Six of these mutants no longer produced disease lesions on primary leaves of the susceptible bean cultivar Red Kidney and failed to elicit a hypersensitive response on the resistant bean cultivar Red Mexican and on the nonhost plants @entity1 , @entity5 , and @entity2 . The two remaining mutants had reduced pathogenicity on Red @entity4 and elicited variable hypersensitive responses on the other plants tested. Southern blot analysis indicated that each mutant carried a single independent Tn5 insertion in one of three EcoRI fragments of about 17, 7, and 5 kilobases. Marker exchange mutagenesis further supported the conclusion that the pleiotropic mutant phenotype was not associated with multiple Tn5 insertions. A genomic library of the wild-type strain was constructed in the cosmid vector pLAFR3. A recombinant plasmid, designated pPL6, that carried @entity3 . "phaseolicola" genomic sequences was identified by colony hybridization. This plasmid restored the wild-type phenotype to all but one mutant, suggesting that genes affected by the insertions were clustered. Structural analysis of pPL6 and the wild-type genome indicated that the 17- and 5-kilobase EcoRI fragments were contiguous in the strain NPS3121 genome.

title: Gene cluster of XXXX . "phaseolicola" controls pathogenicity of bean plants and hypersensitivity of nonhost plants.

answer: @entity3


abstract: PURPOSE: We evaluated single-agent intravenous (IV) @entity5 as first- and second-line treatment for @entity0 ( @entity0 ) in @entity1 who were not resistant to @entity7 . Objective @entity2 response (TR) and @entity3 were assessed. @entity1 AND METHODS: A total of 107 @entity1 were enrolled onto this multicenter, nonrandomized, open-label phase II study. @entity1 were stratified into first- and second-line treatment groups, based on prior treatment history. @entity5 was initially given at 30 mg/m2/wk, with dose modification for @entity3 as indicated. Therapy was continued until disease progression or severe @entity3 mandated withdrawal or until the @entity1 asked to be removed from the study. RESULTS: The objective response rate for all @entity1 was 34% (95% confidence interval [CI], 25% to 44%): 35% (95% CI, 23% to 48%) for first-line @entity1 and 32% (95% CI, 20% to 47%) for second-line @entity1 . Nine first-line and three second-line @entity1 obtained a complete response (CR). The median duration of objective response was 34 weeks in both groups. The overall survival durations of first- and second-line @entity1 were 67 weeks and 62 weeks, respectively. @entity6 was the predominant dose-limiting @entity3 . Two @entity1 died on study as a result of @entity4 . CONCLUSION: Single-agent @entity5 is an effective and well-tolerated agent for first- and second-line therapy of @entity0 . The results of this study confirm the findings of similar international trials and suggest @entity5 should be considered a valid treatment option for @entity1 with @entity0 and a potential component in future combination regimens for this disease.

title: Intravenous @entity5 as first-line and second-line therapy in XXXX .

answer: @entity0


abstract: PURPOSE: We evaluated single-agent intravenous (IV) @entity5 as first- and second-line treatment for @entity0 ( @entity0 ) in @entity1 who were not resistant to @entity7 . Objective @entity2 response (TR) and @entity3 were assessed. @entity1 AND METHODS: A total of 107 @entity1 were enrolled onto this multicenter, nonrandomized, open-label phase II study. @entity1 were stratified into first- and second-line treatment groups, based on prior treatment history. @entity5 was initially given at 30 mg/m2/wk, with dose modification for @entity3 as indicated. Therapy was continued until disease progression or severe @entity3 mandated withdrawal or until the @entity1 asked to be removed from the study. RESULTS: The objective response rate for all @entity1 was 34% (95% confidence interval [CI], 25% to 44%): 35% (95% CI, 23% to 48%) for first-line @entity1 and 32% (95% CI, 20% to 47%) for second-line @entity1 . Nine first-line and three second-line @entity1 obtained a complete response (CR). The median duration of objective response was 34 weeks in both groups. The overall survival durations of first- and second-line @entity1 were 67 weeks and 62 weeks, respectively. @entity6 was the predominant dose-limiting @entity3 . Two @entity1 died on study as a result of @entity4 . CONCLUSION: Single-agent @entity5 is an effective and well-tolerated agent for first- and second-line therapy of @entity0 . The results of this study confirm the findings of similar international trials and suggest @entity5 should be considered a valid treatment option for @entity1 with @entity0 and a potential component in future combination regimens for this disease.

title: Intravenous XXXX as first-line and second-line therapy in @entity0 .

answer: @entity5


abstract: PURPOSE: In a randomized clinical trial (European Organization for the Research and Treatment of Cancer [EORTC] no. 40813) on adjuvant chemotherapy in @entity2 , results obtained after administration of the FAM2 regimen ( @entity5 [ @entity5 ], @entity3 , and @entity4 ) were compared with results obtained after surgery alone to assess the effect of this regimen on overall survival, time to progression, and disease-free interval. @entity0 AND METHODS: Three hundred fourteen @entity0 who had undergone curative resection for stage II or stage III (International Union Against Cancer [UICC] 1978) @entity2 were randomized to receive chemotherapy (treatment arm) or no further treatment (control arm). The chemotherapy schedule was repeated every 43 days for seven cycles. The log-rank test and the Cox model were used for statistical analysis. RESULTS: Of 314 @entity0 , 159 comprised the control group and 155 the FAM2 group. Nineteen FAM2 @entity0 never received chemotherapy. The median number of cycles was five. Of the @entity0 started on adjuvant treatment, severe @entity6 (grades 3 or 4, World Health Organization [WHO] scale) occurred, respectively, in 6% to 9% and in 1% to 29% of cases. The overall 5-year survival rate was 70% for stage II and 32% for stage III @entity0 . No statistically significant difference was found between overall survival of the two treatment arms (P = .295). However, time to progression was significantly delayed in the FAM2 arm (P = .020) and disease-free survival showed borderline significance (P = .068). CONCLUSION: FAM2, in view of its high @entity1 , cannot be advocated as standard adjuvant treatment for @entity2 . Large-scale clinical trials using more active, less toxic regimens are required to demonstrate whether adjuvant chemotherapy provides any real benefit.

title: Final results of a phase III clinical trial of adjuvant chemotherapy with the modified @entity5 , @entity3 , and XXXX regimen in resectable @entity2 .

answer: @entity4


abstract: PURPOSE: In a randomized clinical trial (European Organization for the Research and Treatment of Cancer [EORTC] no. 40813) on adjuvant chemotherapy in @entity2 , results obtained after administration of the FAM2 regimen ( @entity5 [ @entity5 ], @entity3 , and @entity4 ) were compared with results obtained after surgery alone to assess the effect of this regimen on overall survival, time to progression, and disease-free interval. @entity0 AND METHODS: Three hundred fourteen @entity0 who had undergone curative resection for stage II or stage III (International Union Against Cancer [UICC] 1978) @entity2 were randomized to receive chemotherapy (treatment arm) or no further treatment (control arm). The chemotherapy schedule was repeated every 43 days for seven cycles. The log-rank test and the Cox model were used for statistical analysis. RESULTS: Of 314 @entity0 , 159 comprised the control group and 155 the FAM2 group. Nineteen FAM2 @entity0 never received chemotherapy. The median number of cycles was five. Of the @entity0 started on adjuvant treatment, severe @entity6 (grades 3 or 4, World Health Organization [WHO] scale) occurred, respectively, in 6% to 9% and in 1% to 29% of cases. The overall 5-year survival rate was 70% for stage II and 32% for stage III @entity0 . No statistically significant difference was found between overall survival of the two treatment arms (P = .295). However, time to progression was significantly delayed in the FAM2 arm (P = .020) and disease-free survival showed borderline significance (P = .068). CONCLUSION: FAM2, in view of its high @entity1 , cannot be advocated as standard adjuvant treatment for @entity2 . Large-scale clinical trials using more active, less toxic regimens are required to demonstrate whether adjuvant chemotherapy provides any real benefit.

title: Final results of a phase III clinical trial of adjuvant chemotherapy with the modified @entity5 , XXXX , and @entity4 regimen in resectable @entity2 .

answer: @entity3


abstract: PURPOSE: In a randomized clinical trial (European Organization for the Research and Treatment of Cancer [EORTC] no. 40813) on adjuvant chemotherapy in @entity2 , results obtained after administration of the FAM2 regimen ( @entity5 [ @entity5 ], @entity3 , and @entity4 ) were compared with results obtained after surgery alone to assess the effect of this regimen on overall survival, time to progression, and disease-free interval. @entity0 AND METHODS: Three hundred fourteen @entity0 who had undergone curative resection for stage II or stage III (International Union Against Cancer [UICC] 1978) @entity2 were randomized to receive chemotherapy (treatment arm) or no further treatment (control arm). The chemotherapy schedule was repeated every 43 days for seven cycles. The log-rank test and the Cox model were used for statistical analysis. RESULTS: Of 314 @entity0 , 159 comprised the control group and 155 the FAM2 group. Nineteen FAM2 @entity0 never received chemotherapy. The median number of cycles was five. Of the @entity0 started on adjuvant treatment, severe @entity6 (grades 3 or 4, World Health Organization [WHO] scale) occurred, respectively, in 6% to 9% and in 1% to 29% of cases. The overall 5-year survival rate was 70% for stage II and 32% for stage III @entity0 . No statistically significant difference was found between overall survival of the two treatment arms (P = .295). However, time to progression was significantly delayed in the FAM2 arm (P = .020) and disease-free survival showed borderline significance (P = .068). CONCLUSION: FAM2, in view of its high @entity1 , cannot be advocated as standard adjuvant treatment for @entity2 . Large-scale clinical trials using more active, less toxic regimens are required to demonstrate whether adjuvant chemotherapy provides any real benefit.

title: Final results of a phase III clinical trial of adjuvant chemotherapy with the modified XXXX , @entity3 , and @entity4 regimen in resectable @entity2 .

answer: @entity5


abstract: PURPOSE: In a randomized clinical trial (European Organization for the Research and Treatment of Cancer [EORTC] no. 40813) on adjuvant chemotherapy in @entity2 , results obtained after administration of the FAM2 regimen ( @entity5 [ @entity5 ], @entity3 , and @entity4 ) were compared with results obtained after surgery alone to assess the effect of this regimen on overall survival, time to progression, and disease-free interval. @entity0 AND METHODS: Three hundred fourteen @entity0 who had undergone curative resection for stage II or stage III (International Union Against Cancer [UICC] 1978) @entity2 were randomized to receive chemotherapy (treatment arm) or no further treatment (control arm). The chemotherapy schedule was repeated every 43 days for seven cycles. The log-rank test and the Cox model were used for statistical analysis. RESULTS: Of 314 @entity0 , 159 comprised the control group and 155 the FAM2 group. Nineteen FAM2 @entity0 never received chemotherapy. The median number of cycles was five. Of the @entity0 started on adjuvant treatment, severe @entity6 (grades 3 or 4, World Health Organization [WHO] scale) occurred, respectively, in 6% to 9% and in 1% to 29% of cases. The overall 5-year survival rate was 70% for stage II and 32% for stage III @entity0 . No statistically significant difference was found between overall survival of the two treatment arms (P = .295). However, time to progression was significantly delayed in the FAM2 arm (P = .020) and disease-free survival showed borderline significance (P = .068). CONCLUSION: FAM2, in view of its high @entity1 , cannot be advocated as standard adjuvant treatment for @entity2 . Large-scale clinical trials using more active, less toxic regimens are required to demonstrate whether adjuvant chemotherapy provides any real benefit.

title: Final results of a phase III clinical trial of adjuvant chemotherapy with the modified @entity5 , @entity3 , and @entity4 regimen in resectable XXXX .

answer: @entity2


abstract: PURPOSE: To determine the @entity3 , maximal-tolerated dose (MTD), pharmacokinetic profile, and potential antitumor activity of @entity8 , a novel thymidylate synthase (TS) inhibitor. @entity0 AND METHODS: @entity0 with advanced solid @entity1 were administered @entity8 intravenously over 10 minutes, weekly for 4 weeks, every 42 days. Dose escalation was based on the modified continual reassessment method (MCRM), with one @entity0 treated at each minimally toxic dose level. Pharmacokinetic studies were performed in all @entity0 . RESULTS: Twenty-five @entity0 were administered 58 courses of @entity8 at doses that ranged from 10 to 40 mg/m2/wk. Reversible @entity7 was the dose-limiting @entity3 . Inability to maintain the weekly treatment schedule due to @entity7 limited dose escalation on this schedule. Nonhematologic @entity3 observed included mild @entity6 , @entity5 , and @entity4 . At the 40-mg/m2/wk dose level, the mean harmonic half-life, maximum plasma concentration, clearance, and apparent volume of distribution at steady-state were 2.02 hours, 11.20 micrograms/mL, 52.3 mL/min/m2, and 6.64 L/m2, respectively. No major antitumor responses were observed; however, minor responses were achieved in two @entity0 with advanced @entity2 . CONCLUSION: The dose-limiting @entity3 , MTD, and recommended phase II dose of @entity8 when administered weekly for 4 weeks every 42 days are @entity7 , 40 mg/m2, and 30 mg/m2, respectively.

title: Initial phase I evaluation of the novel thymidylate synthase inhibitor, XXXX , using the modified continual reassessment method for dose escalation.

answer: @entity8


abstract: In a prospective randomized trial, we compared the effectiveness of rabbit antithymocyte globulin (RATG) in the treatment of acute renal allograft rejection with the results of treatment by high oral doses of @entity1 . Fifty recipients of cadaveric kidneys were included in each group. In the RATG group, the @entity1 dose was not increased and a dose-by-rosette protocol was used to keep T cell levels between 50 and 150/mm. The three-month and one-year graft survival rates in the RATG group were 84% and 78%, and were significantly higher than those in the @entity1 group (64% and 50%). A significant difference in @entity0 survival could also be detected. In the RATG group the three-months and one-year @entity0 survival rates were 100% and 98%, and @entity0 survival rates in the @entity1 group were 91% and 84%, respectively. The percentage of second rejections was higher in the @entity1 group and 70% of these @entity0 showed a good response to subsequent RATG treatment. Renal function after six months was similar in both groups. No serious side effects were encountered in the RATG group. The incidence of @entity2 was the same in both groups. Treatment of acute rejections with RATG is preferable to @entity1 treatment. It improves long-term graft and @entity0 survival and is steroid-sparing.

title: Improved XXXX and graft survival after treatment of acute rejections of cadaveric renal allografts with rabbit antithymocyte globulin.

answer: @entity0


abstract: Nine homosexual @entity0 with immune @entity2 were treated with autologous plasma that had been perfused over @entity4 -immobilized @entity1 protein A ( @entity5 ). Pretreatment platelet counts ranged from 10,000 to 98,000 cells/mm3 (mean: 54,000 cells/mm3). Six @entity0 responded to therapy. Platelets increased by a mean of 95,000 cells/mm3 (p less than 0.007) and reached normal levels (greater than 150,000 cells/mm3) in four @entity0 . @entity3 are presently sustained in these four individuals after 5 months of follow-up. Increases in platelet counts significantly correlated with decreases in platelet-associated IgG (PAIgG), platelet-directed IgG (PDIgG), and immune complexes (CIC). PAIgG and PDIgG declined by a mean of 67% (p less than 0.003) and 58% (p less than 0.007), respectively. CIC decreased by a mean of 37% (p = 0.02). Complement was concomitantly activated in all four examined @entity0 . C3a and C5a increased 23-fold and 2.6-fold, respectively, while total hemolytic complement decreased by 50%. Activated complement components and removal of CIC and IgG thus may contribute to the platelet-enhancing activity of @entity5 immunoadsorption therapy.

title: Protein A immunoadsorption therapy in HIV-related immune XXXX : a preliminary report.

answer: @entity2


abstract: The current clinical standard of organ respiratory imaging, 4D-CT, is fundamentally limited by poor soft-tissue contrast and imaging dose. These limitations are potential barriers to beneficial "4D" radiotherapy methods which optimize the target and OAR dose-volume considering breathing motion but rely on a robust motion characterization. Conversely, MRI imparts no known radiation risk and has excellent soft-tissue contrast. MRI-based motion management is therefore highly desirable and holds great promise to improve radiotherapy of moving @entity1 , particularly in the abdomen. Over the past decade, MRI techniques have improved significantly, making MR-based motion management clinically feasible. For example, cine MRI has high temporal resolution up to 10 f/s and has been used to track and/or characterize @entity1 motion, study correlation between external and internal motions. New MR technologies, such as 4D-MRI and MRI hybrid treatment machines (i.e. MR-linac or MR-Co60), have been recently developed. These technologies can lead to more accurate target volume determination and more precise radiation dose delivery via direct @entity1 gating or tracking. Despite all these promises, great challenges exist and the achievable clinical benefit of MRI-based @entity1 motion management has yet to be fully explored, much less realized. In this proposal, we will review novel MR-based motion management methods and technologies, the state-of-the-art concerning MRI development and clinical application and the barriers to more widespread adoption. LEARNING OBJECTIVES: 1.Discuss the need of MR-based motion management for improving @entity0 care in radiotherapy.2.Understand MR techniques for motion imaging and @entity1 motion characterization.3.Understand the current state of the art and future steps for clinical integration.Henry Ford Health System holds research agreements with Philips Healthcare. Research sponsored in part by a Henry Ford Health System Internal Mentored Grant.

title: TU-PIS-Exhibit Hall-1: Tools for Collecting and Analyzing XXXX Dose Index Information from Imaging Equipment.

answer: @entity0


abstract: Information regarding the use of brightness-mode (B-mode) ultrasound for separately measuring the thickness of subcutaneous fat and skeletal muscle in the @entity1 area was evaluated. Subjects were volunteers, 32 @entity0 and 32 @entity0 college students. Fat was measured with skinfold calipers and B-mode ultrasound. We used @entity1 circumference and B-mode ultrasound simultaneously to assess muscle size. Ultrasonic measurements of both fat and muscle were repeated within 30 minutes to evaluate reliability. @entity0 were 24 percent heavier than @entity0 but had a thinner fat layer as measured by skinfolds (49%) and ultrasound (29%). @entity0 also had a relatively larger @entity1 muscle as assessed by circumference (7%) and ultrasound (29%). Intraclass correlation coefficients were no less than .99 for repeated ultrasonic measurements of both fat and muscle for @entity0 and @entity0 ; therefore, these procedures are reliable for at least a short period of time. Associations between skinfolds and fat sonograms were high in @entity0 (r = .87) and moderate in @entity0 (r = .50). Associations between circumferences and muscle sonograms were moderately high in both @entity0 (r = .80) and @entity0 (r = .76). All four associations were statistically significant (p less than .05).

title: Ultrasonic protocols for separately measuring subcutaneous fat and skeletal muscle thickness in the XXXX area.

answer: @entity1


abstract: @entity15 is an orally active inhibitor of @entity8 ( @entity8 ) and has been widely studied in the treatment of @entity0 with mild to moderate essential @entity2 , severe @entity2 not responsive to conventional diuretic/beta-adrenoceptor blocker/vasodilator regimens, and @entity0 with chronic @entity5 refractory to treatment with a diuretic and digitalis. In @entity0 with mild or moderate essential @entity2 , titrated low doses of @entity15 used alone or in conjunction with a diuretic are similar in efficacy to usual doses of @entity6 , @entity17 , or beta-adrenoceptor blocking drugs, as well as to the other @entity8 inhibitors. In addition, @entity15 improved well-being to a greater extent than @entity19 or @entity7 in a study designed specifically to determine the effect of treatment on the quality of life of @entity0 with mild or moderate essential @entity2 . The earlier demonstrated efficacy of @entity15 , used with a diuretic and often also with a beta-adrenoceptor blocking drug, in the treatment of severe @entity2 refractory to conventional 'triple therapy' has been confirmed in more recent trials which illustrate the generally marked antihypertensive effect of @entity15 -containing regimens in such @entity0 . Results of initial trials in @entity0 with @entity13 are promising, with control of @entity2 and stabilization of renal function in these @entity0 when treated at an early stage of the disease. Several comparative and long term trials of @entity15 in @entity0 with chronic @entity5 refractory to treatment with a diuretic/digitalis regimen clearly demonstrate that initial haemodynamic improvement is maintained and correlates with clinical benefit. A tendency for overall clinical response to @entity15 to be better than the response to @entity14 , @entity12 , @entity18 or @entity16 has been reported. Results of a multicentre comparison with digoxin and placebo indicate that @entity15 is a suitable alternative to digoxin in @entity0 with mild to moderate @entity5 who are receiving maintenance diuretic therapy. The tolerability of @entity15 has now been studied in many thousands of @entity0 involved in formalized trials and the early impression of poor tolerability can no longer be justified. The use of generally lower dosages of @entity15 in @entity0 with normal or slightly @entity1 has resulted in a generally low incidence of @entity10 (0.5 to 4%), @entity11 (0.1 to 3%), @entity4 (0.5%), @entity9 (0.3% during first 3 months) and symptomatic @entity3 (0.1 to 3%). Cough is an infrequent but troublesome effect resulting from @entity8 inhibition.(ABSTRACT TRUNCATED AT 400 WORDS)

title: @entity15 . An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in @entity2 and XXXX .

answer: @entity5


abstract: @entity15 is an orally active inhibitor of @entity8 ( @entity8 ) and has been widely studied in the treatment of @entity0 with mild to moderate essential @entity2 , severe @entity2 not responsive to conventional diuretic/beta-adrenoceptor blocker/vasodilator regimens, and @entity0 with chronic @entity5 refractory to treatment with a diuretic and digitalis. In @entity0 with mild or moderate essential @entity2 , titrated low doses of @entity15 used alone or in conjunction with a diuretic are similar in efficacy to usual doses of @entity6 , @entity17 , or beta-adrenoceptor blocking drugs, as well as to the other @entity8 inhibitors. In addition, @entity15 improved well-being to a greater extent than @entity19 or @entity7 in a study designed specifically to determine the effect of treatment on the quality of life of @entity0 with mild or moderate essential @entity2 . The earlier demonstrated efficacy of @entity15 , used with a diuretic and often also with a beta-adrenoceptor blocking drug, in the treatment of severe @entity2 refractory to conventional 'triple therapy' has been confirmed in more recent trials which illustrate the generally marked antihypertensive effect of @entity15 -containing regimens in such @entity0 . Results of initial trials in @entity0 with @entity13 are promising, with control of @entity2 and stabilization of renal function in these @entity0 when treated at an early stage of the disease. Several comparative and long term trials of @entity15 in @entity0 with chronic @entity5 refractory to treatment with a diuretic/digitalis regimen clearly demonstrate that initial haemodynamic improvement is maintained and correlates with clinical benefit. A tendency for overall clinical response to @entity15 to be better than the response to @entity14 , @entity12 , @entity18 or @entity16 has been reported. Results of a multicentre comparison with digoxin and placebo indicate that @entity15 is a suitable alternative to digoxin in @entity0 with mild to moderate @entity5 who are receiving maintenance diuretic therapy. The tolerability of @entity15 has now been studied in many thousands of @entity0 involved in formalized trials and the early impression of poor tolerability can no longer be justified. The use of generally lower dosages of @entity15 in @entity0 with normal or slightly @entity1 has resulted in a generally low incidence of @entity10 (0.5 to 4%), @entity11 (0.1 to 3%), @entity4 (0.5%), @entity9 (0.3% during first 3 months) and symptomatic @entity3 (0.1 to 3%). Cough is an infrequent but troublesome effect resulting from @entity8 inhibition.(ABSTRACT TRUNCATED AT 400 WORDS)

title: @entity15 . An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in XXXX and @entity5 .

answer: @entity2


abstract: @entity15 is an orally active inhibitor of @entity8 ( @entity8 ) and has been widely studied in the treatment of @entity0 with mild to moderate essential @entity2 , severe @entity2 not responsive to conventional diuretic/beta-adrenoceptor blocker/vasodilator regimens, and @entity0 with chronic @entity5 refractory to treatment with a diuretic and digitalis. In @entity0 with mild or moderate essential @entity2 , titrated low doses of @entity15 used alone or in conjunction with a diuretic are similar in efficacy to usual doses of @entity6 , @entity17 , or beta-adrenoceptor blocking drugs, as well as to the other @entity8 inhibitors. In addition, @entity15 improved well-being to a greater extent than @entity19 or @entity7 in a study designed specifically to determine the effect of treatment on the quality of life of @entity0 with mild or moderate essential @entity2 . The earlier demonstrated efficacy of @entity15 , used with a diuretic and often also with a beta-adrenoceptor blocking drug, in the treatment of severe @entity2 refractory to conventional 'triple therapy' has been confirmed in more recent trials which illustrate the generally marked antihypertensive effect of @entity15 -containing regimens in such @entity0 . Results of initial trials in @entity0 with @entity13 are promising, with control of @entity2 and stabilization of renal function in these @entity0 when treated at an early stage of the disease. Several comparative and long term trials of @entity15 in @entity0 with chronic @entity5 refractory to treatment with a diuretic/digitalis regimen clearly demonstrate that initial haemodynamic improvement is maintained and correlates with clinical benefit. A tendency for overall clinical response to @entity15 to be better than the response to @entity14 , @entity12 , @entity18 or @entity16 has been reported. Results of a multicentre comparison with digoxin and placebo indicate that @entity15 is a suitable alternative to digoxin in @entity0 with mild to moderate @entity5 who are receiving maintenance diuretic therapy. The tolerability of @entity15 has now been studied in many thousands of @entity0 involved in formalized trials and the early impression of poor tolerability can no longer be justified. The use of generally lower dosages of @entity15 in @entity0 with normal or slightly @entity1 has resulted in a generally low incidence of @entity10 (0.5 to 4%), @entity11 (0.1 to 3%), @entity4 (0.5%), @entity9 (0.3% during first 3 months) and symptomatic @entity3 (0.1 to 3%). Cough is an infrequent but troublesome effect resulting from @entity8 inhibition.(ABSTRACT TRUNCATED AT 400 WORDS)

title: XXXX . An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in @entity2 and @entity5 .

answer: @entity15


abstract: PURPOSE: @entity2 tracking is an advanced technique to treat intra-fractionally moving @entity2 . The aim of this study is to validate a surrogate-driven model based on four-dimensional computed tomography (4DCT) that is able to predict CT volumes corresponding to arbitrary respiratory states. Further, the comparison of three different driving surrogates is evaluated. METHODS: This study is based on multiple 4DCTs of two @entity0 treated for @entity3 and @entity1 . Analyses for 18 additional @entity0 are currently ongoing. The motion model was estimated from the planning 4DCT through deformable image registration. To predict a certain phase of a follow-up 4DCT, the model considers for inter-fractional variations (baseline correction) and intra-fractional respiratory parameters (amplitude and phase) derived from surrogates. In this evaluation, three different approaches were used to extract the motion surrogate: for each 4DCT phase, the 3D thoraco-abdominal surface motion, the body volume and the anterior-posterior motion of a virtual single external marker defined on the sternum were investigated. The estimated volumes resulting from the model were compared to the ground-truth clinical 4DCTs using absolute HU differences in the lung volume and landmarks localized using the Scale Invariant Feature Transform (SIFT). RESULTS: The results show absolute HU differences between estimated and ground-truth images with median values limited to 55 HU and inter-quartile ranges (IQR) lower than 100 HU. Median 3D distances between about 1500 matching landmarks are below 2 mm for 3D surface motion and body volume methods. The single marker surrogates Result in increased median distances up to 0.6 mm. Analyses for the extended database incl. 20 @entity0 are currently in progress. CONCLUSION: The results depend mainly on the image quality of the initial 4DCTs and the deformable image registration. All investigated surrogates can be used to estimate follow-up 4DCT phases, however uncertainties decrease for three-dimensional approaches. This work was funded in parts by the German Research Council (DFG) - KFO 214/2.

title: WE-AB-303-11: Verification of a Deformable 4DCT Motion Model for Lung XXXX Tracking Using Different Driving Surrogates.

answer: @entity2


abstract: OBJECTIVES: This study sought to assess the usefulness and accuracy of artificial @entity3 in the prognosis of 1-year mortality in @entity0 with @entity2 . BACKGROUND: Artificial @entity3 is a computational technique used to represent and process information by means of networks of interconnected processing elements, similar to neurons. They have found applications in medical decision support systems, particularly in prognosis. METHODS: Clinical and Doppler-derived echocardiographic data from 95 consecutive @entity0 with diffuse impairment of @entity1 were studied. After 1 year, data regarding survival or death were obtained and produced the prognostic variable. The data base was divided randomly into a training data set (47 cases, 8 deaths) and a testing data set (48 cases, 7 deaths). Results of artificial neural network classification were compared with those from linear discriminant analysis, clinical judgment and conventional heuristically based programs. RESULTS: The study group included 57 male (47 survivors) and 38 female @entity0 (33 survivors). Linear discriminant analysis was not efficient for separating survivors from nonsurvivors because the accuracy at the ideal cutoff value was only 67.4%, with a sensitivity of 67.5%, positive predictive value of 27.8% and negative predictive value of 91.5%. In contrast, all artificial @entity3 were able to predict outcome with an accuracy of 90%, specificity of 93% and sensitivity of 71.4%, for the best artificial neural network. Both clinical judgment and automatic heuristic methods were also inferior in performance. CONCLUSIONS: The artificial neural network method has proved to be reliable for implementing quantitative prognosis of mortality in @entity0 with @entity2 . Additional studies with larger numbers of @entity0 are required to better assess the usefulness of artificial @entity3 .

title: One-year mortality prognosis in XXXX : a neural network approach based on echocardiographic data.

answer: @entity2


abstract: PURPOSE: @entity1 proliferate and invade healthy brain tissue rapidly, yielding short life expectancies. Radiation therapy is commonly used, but @entity2 are known to be radio-resistant, and almost always recur following treatment. Current radiotherapy protocols are based on the classic linear-quadratic radiobiological model, assuming a @entity1 . @entity2 are very heterogeneous, consisting of normoxic, @entity4 , and @entity3 tissues, each responding differently to radiation. An enhanced linear-quadratic model which takes into account the different responses of the heterogeneous @entity1 regions to radiation can guide treatment planning to optimize dose distributions to maximize the therapeutic effect. METHODS: We used a set of differential equations to model the growth of @entity1 . Our model expands on the one-component model developed by (Rockne,2010) by including normoxic, @entity4 , and @entity3 components and radiosensitivity values for each component. Proliferation and diffusion parameters are extracted by contouring the @entity1 on two sets of pre-treatment MRIs and modeling it as a volume equivalent sphere. RESULTS: We compared two examples of @entity1 presented in (Rockne,2010) with our three component model and find better predictive capabilities for post-RT @entity1 volumes using the three component model. In both cases, the one-component model over predicts the effects of radiation on the @entity1 core, while the three-component model more accurately fits the data by accounting for radioresistance of the @entity4 core. Additionally, we applied the model to a UCSF @entity0 with a recurring @entity1 and use the model to predict time to fatal @entity1 burden. CONCLUSION: The three-component model accurately matches @entity1 growth dynamics derived from MRIs for two example cases presented in literature, and one case from UCSF. Spatial information about @entity4 , @entity3 , and normoxic cell densities are derived from the model providing information needed to more intelligently prescribe dose distributions tailored to a specific @entity0 's @entity1 .[Rockne,et.al.,PhysMedBio,2010].

title: TH-AB-304-09: A XXXX -Specific Heterogeneous Radiobiological Model for Glioblastoma Multiforme.

answer: @entity0


abstract: PURPOSE: The purpose of this manuscript is to investigate the dosimetric and clinical benefits of a technique by combining conformal radiotherapy (CRT) plus volumetric modulated arc therapy (VMAT) in the treatment of @entity3 ( @entity3 ). METHODS: There were 200 @entity3 @entity0 analyzed retrospectively and treated by CRT, CRT plus VMAT, and full course of VMAT, respectively. Dosimetric differences, @entity4 ( @entity4 ) rates and their correlation were investigated. RESULTS: The number of @entity0 analyzed in CRT, CRT plus VMAT and full course of VMAT were 42, 28, and 53, respectively. The V93 and V95 (percent volume covered by isodose line) of planning target volume ( @entity1 ) were improved from 95.7%  2.2% and 94.5%  2.4% in CRT to 97.9%  4.6%, 98.3%  3.2% and 96.3%  5.8%, 97.1%  4.1% in CRT plus VMAT and full course of VMAT, respectively. CRT plus VMAT improved the @entity1 coverage compared with CRT in a cost of higher spinal cord maximum dose (p=0.02), larger lung volume receiving 5 Gy (V5, p=0.02) and @entity2 ( @entity2 ) (p=0.04), and decreased the low dose lung volumes compared with VMAT. The @entity4 rates were 26%, 39% and 49% for CRT, CRT plus VMAT and VMAT, respectively. V5 was significantly associated with @entity4 and had a threshold of 60% and 65% for CRT plus VMAT and VMAT, respectively, to limit the @entity4 rate <30%. CONCLUSION: CRT plus VMAT is a promising with increased target coverage compared with CRT and reduced low dose lung volume and @entity4 compared with full course of VMAT in the treatment of @entity3 . V5 was significantly associated with @entity4 and with a predicted threshold of 60% and 65% for CRT plus VMAT and VMAT, respectively, to limit the @entity4 rate <30%. Clinical trials with large population are needed to further verify the benefits of CRT plus VMAT in the treatment of @entity3 .

title: TH-AB-BRB-04: Dosimetric and Clinical Benefits of Conformal Radiotherapy Plus Volumetric Modulated Arc Therapy in the Treatment of XXXX .

answer: @entity3


abstract: PURPOSE: Converting theoretical fluence maps to deliverable @entity2 segments while maintaining plan quality has posed a significant challenge for highly complex IMRT plans involving many fields. Rather than simplifying individual fluence maps, we have formulated the problem as a global dose domain fluence map optimization with anisotropic total variation regularization (FMOATVR) problem and then solve the large scale optimization problem. METHODS: The 4   planning platform was used to select and optimize 20 non-coplanar beams for 2 GBM, 2 head _ neck, and 2 lung @entity0 with varying prescription doses, including H_N case #2 that had 3 prescription dose levels of 54 Gy, 59.4 Gy, and 69.96 Gy. The plans were re-run using FMOATVR and the same 20 4   beams. The L2 norm of dose deviation from the ideal prescription with zero dose to OARs was used as the objective function, which was subjected to anisotropic total variation regularization to encourage piecewise smoothness in the fluence maps. The fluences were stratified into equal step sizes to create 300 @entity2 segments. The dose distributions were normalized so the prescription dose covered cover 95% of the @entity1 . H_N case #2 was normalized to cover the 59.4 Gy @entity1 , which was included in the statistics. RESULTS: Compared to the directly stratified 4   plans (4   DS), the 4   FMOATVR method reduced the average mean and max dose to the OARs by 3.54% and 4.15%, respectively, of the prescription dose. Dose coverage was also improved, evidenced by an average D98 and D99 increase of 1.63% and 2.74% of the prescription dose, respectively. The average @entity1 homogeneity was increased from 0.833 to 0.905. CONCLUSION: The global dose domain fluence map optimization formula and its solver provides a straightforward yet potent method to attain high quality while remaining robust to @entity2 segmentation for complex IMRT. This work is supported in part by Varian Medical Systems, Inc.

title: TH-EF-BRD-05: A New Intensity Modulation Radiation Therapy (IMRT) Optimizer Solution with Robust Fluence Maps for XXXX Segmentation.

answer: @entity2


abstract: The Society for Cardiac Angiography maintains a registry of intracoronary streptokinase therapy (IC-SK) in @entity0 with @entity2 . Between July 1981 and August 1984, 1,029 @entity0 were entered into the registry. The baseline and clinical characteristics of @entity0 were determined, the early results of therapy were evaluated, and baseline characteristics of those in whom reperfusion was achieved were compared with those in whom it was not. Multivariate discriminant analysis was used to identify the predictors of reperfusion and hospital mortality. The overall rate of reperfusion was 71.2%. Reperfusion was positively associated with @entity1 , @entity3 and early treatment. The hospital mortality rate for all @entity0 was 8.2% and was higher for @entity0 and the elderly. The hospital mortality was significantly lower among @entity0 in whom reperfusion was achieved compared with those in whom it was not (5.5% vs 14.7%, p less than 0.0001) and for several high-risk subgroups. Thus, coronary artery reperfusion induced by IC-SK significantly reduces hospital mortality in high-risk @entity0 with @entity2 . High-risk @entity0 in whom reperfusion fails with IC-SK therapy should be considered for early coronary angioplasty or coronary artery bypass surgery.

title: Acute XXXX treated with intracoronary streptokinase: a report of the Society for Cardiac Angiography.

answer: @entity2


abstract: AIMS: @entity4 perception is considered to provide a measure of social cognition. Numerous studies have examined the perception of emotion in @entity0 with @entity3 , and the majority has reported impaired ability to recognize facial emotion perception. We aimed to investigate the correlation between facial expression recognition and other domains of social cognition and neurocognition in Japanese @entity0 with @entity3 . METHODS: @entity0 were 52 @entity0 with @entity3 and 53 normal controls with no history of @entity2 . All @entity0 completed the Hinting Task and the Social Cognition Screening Questionnaire. The Brief Assessment of Cognition in @entity3 was administered only to the @entity0 . @entity4 perception measured by the Facial Emotion Selection Test (FEST) was compared between the @entity0 and normal controls. RESULTS: @entity0 performed significantly worse on the FEST compared to normal control subjects. The FEST total score was significantly positively correlated with scores of the Brief Assessment of Cognition in @entity3 attention subscale, Hinting Task, Social Cognition Screening Questionnaire Verbal Working Memory and Metacognition subscales. Stepwise multiple regression analysis revealed that @entity1 was positively related to the facial emotion perception ability in @entity0 with @entity3 . CONCLUSIONS: These results point to the concept that facial emotion perception and some types of working memory use common cognitive resources. Our findings may provide implications for cognitive rehabilitation and related interventions in @entity3 .

title: Facial expression perception correlates with @entity1 in XXXX .

answer: @entity3


abstract: AIMS: @entity4 perception is considered to provide a measure of social cognition. Numerous studies have examined the perception of emotion in @entity0 with @entity3 , and the majority has reported impaired ability to recognize facial emotion perception. We aimed to investigate the correlation between facial expression recognition and other domains of social cognition and neurocognition in Japanese @entity0 with @entity3 . METHODS: @entity0 were 52 @entity0 with @entity3 and 53 normal controls with no history of @entity2 . All @entity0 completed the Hinting Task and the Social Cognition Screening Questionnaire. The Brief Assessment of Cognition in @entity3 was administered only to the @entity0 . @entity4 perception measured by the Facial Emotion Selection Test (FEST) was compared between the @entity0 and normal controls. RESULTS: @entity0 performed significantly worse on the FEST compared to normal control subjects. The FEST total score was significantly positively correlated with scores of the Brief Assessment of Cognition in @entity3 attention subscale, Hinting Task, Social Cognition Screening Questionnaire Verbal Working Memory and Metacognition subscales. Stepwise multiple regression analysis revealed that @entity1 was positively related to the facial emotion perception ability in @entity0 with @entity3 . CONCLUSIONS: These results point to the concept that facial emotion perception and some types of working memory use common cognitive resources. Our findings may provide implications for cognitive rehabilitation and related interventions in @entity3 .

title: Facial expression perception correlates with XXXX in @entity3 .

answer: @entity1


abstract: Binding equilibria for the interactions of the @entity2 anions, laurate and myristate, with defatted human serum albumin have been investigated under varying environmental conditions such as ionic strength and pH. Since these ligands bind strongly to albumin (Kass approximately 10(7) M-1), conventional equilibrium dialysis is not a feasible method for these investigations. Consequently, we employed a dialysis method, allowing determination of very low concentrations of unbound ligand by measuring the rate of exchange of labelled ligand across a dialysis membrane under conditions of chemical equilibrium. Over a range of ionic strength, 8-68 mM, the binding of the first few molecules of laurate to albumin was weakened with increasing ionic strength, whereas the binding of subsequent molecules seemed to proceed independently of ionic strength. The binding of myristate by albumin, however, appeared to be independent of ionic strength in the observed range of concentrations. The influence of pH in the range 5.1-9.0 on the binding of the two @entity1 anions by albumin was more complicated. The first molecule of @entity3 appeared to bind with a slightly weaker affinity to albumin at low pH, compared to pH 7 and high pH, while the trends for the following molecules varied. The binding of myristate (irrespective of concentration) seemed to strengthen monotonously with pH, but this conclusion depends critically on the interpretation of the kinetic behaviour of the myristate anion. We have previously shown [Pedersen, A. O., Honor  , B. _ Brodersen, R. (1990) Eur. J. Biochem. 190, 497-502] that the strength of binding of the first few molecules of the two @entity1 anions to albumin decreases with increasing temperature, whereas binding of subsequent molecules seems to proceed independently of temperature. We explain these findings as follows. The binding of the first few (3 or 4) molecules of the C12 laurate anion is clearly driven by formation of ionic bonds between the @entity1 anion and positively charged groups, such as @entity0 residues, in the albumin molecule, whereas the binding of subsequent molecules of laurate seems to depend more on hydrophobic interactions. In the case of the C14 myristate anion, the binding of the first few (only 1 or 2) molecules may depend on ionic forces, but binding of the following molecules of myristate seems to depend on hydrophobic interactions only.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Effects of ionic strength and pH on the binding of XXXX to human serum albumin.

answer: @entity2


abstract: OBJECTIVE: @entity0 with healed @entity7 often experience recurrence of @entity4 , despite the use of long-term compression therapy. This study examines the effect of closing incompetent perforating veins (IPVs) on @entity4 recurrence rates in @entity0 with progressive @entity8 and impending @entity4 . METHODS: @entity0 with nonhealing @entity7 of >2 months' duration underwent duplex ultrasound to assess their lower extremity venous system for @entity3 of superficial, perforating, and deep veins. Endovenous laser ablation (EVLA) of perforating veins was performed on @entity0 with @entity9 6 disease with @entity6 , @entity8 , and/or progressive @entity1 . A minimum of 2 months of compressive therapy was attempted before endovenous ablation of IPVs. Demographic data, risk factors, @entity9 classification, procedural details, and postoperative status were all recorded. RESULTS: Forty ulcers with 46 associated IPVs were treated with EVLA in 36 @entity0 with @entity9 6 recalcitrant @entity7 . Treated incompetent perforator veins were located in the medial ankle (85.7%), @entity2 (10.7%), and lateral ankle (3.5%). Endovenous laser ablation was successful in 76% (35/46) with the first laser treatment of incompetent perforator veins and 15.2% (7/46) additional ablation procedures were performed. Of the 46 treated IPVs, 42 (91.3%) were occluded on the duplex examination at 12 months. The average energy administrated per perforating vein treated was 162 joule. Two @entity0 reported localized paresthesia, which subsided spontaneously, but no @entity5 or skin burn was observed. CONCLUSION: Especially in the case of liposclerotic or ulcerated skin in the affected region, PAP of IPVs is highly effective, safe, and appears to be feasible. @entity0 with @entity7 appear to benefit from EVLA of incompetent perforators in order to reduce the risk of @entity4 recurrence.

title: Combined treatment with endovenous laser ablation and compression therapy of incompetent perforating veins for treatment of recalcitrant XXXX .

answer: @entity7


abstract: BACKGROUND: @entity6 currently accounts for one-half of viridans streptococci. Treatment has become complicated due to the increase in resistance to @entity2 and @entity8 . The aim of the study was to assess the efficacy of various antibiotics as monotherapy and in association with @entity4 , in a experimental model of @entity5 in @entity1 . The effects were compared with a control group and a group given classical @entity2 - @entity4 treatment. MATERIAL AND METHODS: @entity5 was induced in 180 @entity1 with a clinical isolate of @entity6 . Treatment was started 48 h after infection, and lasted 5 days. The animals were divided into nine groups of 20 @entity1 : G1, untreated controls; G2, @entity2 - @entity4 ; G3, @entity10 - @entity4 ; G4, @entity9 ; G5, @entity9 - @entity4 ; G6, @entity11 ; G7, @entity11 - @entity4 ; G8, @entity7 and G9, @entity7 - @entity4 . Response to therapy was evaluated by mortality curves, as negative blood cultures, concentration of @entity6 in aortic vegetations and rate of sterilization of vegetations. RESULTS: Vegetation weight was significantly lower in treated groups than in controls; lower weights were found in G5, 6, and 9. G9 sterilized 75% of the vegetations. @entity3 occurred in 25% of the control group and in 4.76% of G6 and 7. Blood cultures became negative most rapidly in G9. CONCLUSIONS: Combined treatment with @entity7 - @entity4 may be highly efficacious in @entity0 with @entity5 caused by @entity2 -resistant @entity6 . Other combinations, such as @entity9 - @entity4 and @entity11 - @entity4 , may be also advantageous.

title: Treatment with various antibiotics of experimental @entity5 caused by @entity2 -resistant XXXX .

answer: @entity6


abstract: BACKGROUND: @entity6 currently accounts for one-half of viridans streptococci. Treatment has become complicated due to the increase in resistance to @entity2 and @entity8 . The aim of the study was to assess the efficacy of various antibiotics as monotherapy and in association with @entity4 , in a experimental model of @entity5 in @entity1 . The effects were compared with a control group and a group given classical @entity2 - @entity4 treatment. MATERIAL AND METHODS: @entity5 was induced in 180 @entity1 with a clinical isolate of @entity6 . Treatment was started 48 h after infection, and lasted 5 days. The animals were divided into nine groups of 20 @entity1 : G1, untreated controls; G2, @entity2 - @entity4 ; G3, @entity10 - @entity4 ; G4, @entity9 ; G5, @entity9 - @entity4 ; G6, @entity11 ; G7, @entity11 - @entity4 ; G8, @entity7 and G9, @entity7 - @entity4 . Response to therapy was evaluated by mortality curves, as negative blood cultures, concentration of @entity6 in aortic vegetations and rate of sterilization of vegetations. RESULTS: Vegetation weight was significantly lower in treated groups than in controls; lower weights were found in G5, 6, and 9. G9 sterilized 75% of the vegetations. @entity3 occurred in 25% of the control group and in 4.76% of G6 and 7. Blood cultures became negative most rapidly in G9. CONCLUSIONS: Combined treatment with @entity7 - @entity4 may be highly efficacious in @entity0 with @entity5 caused by @entity2 -resistant @entity6 . Other combinations, such as @entity9 - @entity4 and @entity11 - @entity4 , may be also advantageous.

title: Treatment with various antibiotics of experimental @entity5 caused by XXXX -resistant @entity6 .

answer: @entity2


abstract: BACKGROUND: @entity6 currently accounts for one-half of viridans streptococci. Treatment has become complicated due to the increase in resistance to @entity2 and @entity8 . The aim of the study was to assess the efficacy of various antibiotics as monotherapy and in association with @entity4 , in a experimental model of @entity5 in @entity1 . The effects were compared with a control group and a group given classical @entity2 - @entity4 treatment. MATERIAL AND METHODS: @entity5 was induced in 180 @entity1 with a clinical isolate of @entity6 . Treatment was started 48 h after infection, and lasted 5 days. The animals were divided into nine groups of 20 @entity1 : G1, untreated controls; G2, @entity2 - @entity4 ; G3, @entity10 - @entity4 ; G4, @entity9 ; G5, @entity9 - @entity4 ; G6, @entity11 ; G7, @entity11 - @entity4 ; G8, @entity7 and G9, @entity7 - @entity4 . Response to therapy was evaluated by mortality curves, as negative blood cultures, concentration of @entity6 in aortic vegetations and rate of sterilization of vegetations. RESULTS: Vegetation weight was significantly lower in treated groups than in controls; lower weights were found in G5, 6, and 9. G9 sterilized 75% of the vegetations. @entity3 occurred in 25% of the control group and in 4.76% of G6 and 7. Blood cultures became negative most rapidly in G9. CONCLUSIONS: Combined treatment with @entity7 - @entity4 may be highly efficacious in @entity0 with @entity5 caused by @entity2 -resistant @entity6 . Other combinations, such as @entity9 - @entity4 and @entity11 - @entity4 , may be also advantageous.

title: Treatment with various antibiotics of experimental XXXX caused by @entity2 -resistant @entity6 .

answer: @entity5


abstract: INTRODUCTION: @entity2 is a rare but serious complication following elective surgery. The purpose of this study was to identify the rate of @entity2 following elective laparoscopic gastric bypass (LGBP) and to identify @entity0 ' modifiable, preoperative risk factors. METHODS: The American College of Surgeons National Surgical Quality Improvement Program database was queried from 2005 to 2013 for factors associated with the development of @entity2 following elective LGBP. @entity0 who developed @entity6 were compared to those who did not. Results were analyzed using the Chi-square test for categorical variables and Wilcoxon two-sample test for continuous variables. A multivariate logistic regression analysis was utilized to calculate adjusted odds ratios for factors contributing to @entity6 . RESULTS: During the study period, 66,838 @entity0 underwent LGBP. Of those, 546 @entity0 developed @entity2 (0.82  %). The development of @entity6 was associated with increased operative time (161      77.8 vs. 135.10      56.5  min; p  <  0.0001) and a greater number of preoperative comorbidities, including @entity1 (39.6 vs. 30.6  %; p  <  0.0001), @entity3 requiring medication (65.2 vs. 54  %; p  <  0.0001), current @entity5 use (16.7 vs. 11.5  %; p  =  0.0002), and increased pack-year history of smoking (8.6      18.3 vs. 5.6      14.2; p  =  0.0006), and the Charlson Comorbidity Index (0.51      0.74 vs. 0.35      0.57, p  <  0.0001). @entity6 resulted in an increased length of stay (10.1      14.4 vs. 2.4      4.8  days; p  <  0.0001) and a 30 times greater chance of 30-day mortality (4.03 vs. 0.11  %, p  <  0.0001). Multivariate logistic regression analysis showed that current smokers had a 63  % greater chance of developing @entity6 compared to non-smokers, controlling for age, race, gender, BMI, and CCI score (OR 1.63, 95  % CI 1.23-2.14; p  =  0.0006). CONCLUSIONS: Laparoscopic gastric bypass is uncommonly associated with @entity2 . When it occurs, it portends a 30 times increased risk of @entity4 . A @entity0 history of @entity1 , @entity3 , and increasing pack-years of smoking portend an increased risk of @entity6 . Current smoking status, a preoperative modifiable risk factor, is independently associated with the chance of @entity2 . Preoperative @entity0 optimization and risk reduction should be a priority for elective surgery, and @entity0 should be encouraged to stop smoking prior to gastric bypass.

title: Risk factors for XXXX in laparoscopic gastric bypass.

answer: @entity2


abstract: PURPOSE/OBJECTIVES: A report of clinical outcomes of a computed tomography (CT)-based image guided brachytherapy (IGBT) technique for treatment of @entity1 . METHODS AND MATERIALS: Seventy-six @entity0 with International Federation of Gynecology and Obstetrics stage IB to IVA cervical @entity3 diagnosed between 2007 and 2014 were treated with definitive external beam radiation therapy (EBRT) with or without concurrent chemotherapy followed by high-dose-rate (HDR) IGBT. All @entity0 underwent planning CT simulation at each implantation. A high-risk clinical target volume ( @entity5 ) encompassing any visible @entity1 and the entire cervix was contoured on the simulation CT. When available, magnetic resonance imaging (MRI) was performed at implantation to assist with @entity1 delineation. The prescription dose was prescribed to the @entity5 . RESULTS: The median follow-up time was 17  months. Thirteen @entity0 (17%) had an MRI done before brachytherapy, and 16 @entity0 (21%) were treated without MRI guidance. The mean EBRT/IGBT sum 2-Gy equivalent dose (EQD2) delivered to the 90% volume of the @entity5 was 86.3  Gy. The mean maximum EQD2s delivered to 2  cm(3) of the rectum, sigmoid, and bladder were 67.5  Gy, 66.2  Gy, and 75.3  Gy, respectively. The 2-year cumulative incidences of local, locoregional, and distant failure were 5.8% (95% confidence interval [CI]: 1.4%-14.8%), 15.1% (95% CI: 5.4%-29.4%), and 24.3% (95% CI: 12.1%-38.9%), respectively. The 2-year overall and disease-free survival rates were 75% (95% CI, 61%-91%) and 73% (95% CI, 60%-90%), respectively. Twenty-nine @entity0 (38%) experienced grade >= 2 acute @entity2 , with 5 cases of acute grade 3 @entity2 and no grade >= 4 @entity2 . One @entity0 experienced grade 3 @entity4 . No other late grade >= 3 events were observed. CONCLUSIONS: This is the largest report to date of CT/MRI-based IGBT for the treatment of @entity1 . The results are promising, with excellent local control and acceptable @entity2 . Further investigation is needed to assess the long-term safety and efficacy of this treatment.

title: Clinical Outcomes of Computed Tomography-Based Volumetric Brachytherapy Planning for XXXX .

answer: @entity1


abstract: Following the well-known European CCRs of Manchester and Turin, 2 regional CCRs have been recently created in France: in Nancy (1983) and Marseille (1984); both are population based CCRs, covering respectively 535,200 and 809,200 @entity0 (0-14 yrs). All @entity1 are included, as well as @entity2 (whatever grading) and borderline @entity1 . Data are collected from medical and administrative sources. Registration is active and every source is recontacted annually. The registries contact all physicians who might include @entity0 among their @entity0 (private and hospital practice), and laboratories of pathology-cytology. The University Hospital Centers and Anti- @entity1 Centers in adjacent regions, and in Paris are contacted. Death certificates for @entity0 dying of a @entity1 are also sent to the registry. Data collected are as follows: name, age, sex, address, date and method of diagnosis, histological type, anatomical site, stage, treatment and sources of information. We added the data of a general @entity1 registry, created in Strasbourg in 1975 and covering 205,900 @entity0 . reliability of the methodology is attested by the similarity of the results obtained in other European, US and Australian CCRs. In conclusion, this type of registry is needed to organize multicentric epidemiological studies about the role of etiological factors, the survival, and the long term sequelae.

title: [Childhood XXXX registries in France].

answer: @entity1


abstract: OBJECTIVE: We investigated the effectiveness of a right hemispheric surgical approach in treating unruptured anterior communicating @entity1 . METHODS: Between January 2005 and June 2012, 305 @entity0 with anterior communicating artery (Acom) @entity2 were treated using the pterional approach. Among them, 113 who underwent microsurgery with an unruptured Acom @entity2 were enrolled in this study. Every @entity0 was evaluated with digital subtraction angiography preoperatively and CT scans were taken several times postoperatively. Surgical outcomes and complications were evaluated at discharge using the Glasgow Outcome Scale and at 6 months after surgery with CT angiography. RESULTS: Enrolled @entity0 included 55 males and 58 females with a mean age of 56.3 years (range: 30-75 years). The mean diameter of the @entity2 was 5.8mm (range: 1.9-24.1). Left A1 dominancy was found in 71 @entity0 (62.8%) whereas right A1 dominancy was found in 20 @entity0 (17.7%), and right pterional craniotomies were performed in 92 @entity0 (81.4%) while left pterional craniotomies were performed in 21 @entity0 (18.6%). Complete clip application was achieved in 94.9% of @entity0 (74 of 78) in right-side approach group but in only 81.3% of @entity0 (13 of 16) in left-side approach group. Despite a left A1 dominancy and approached from the right, more than 90% of the @entity0 had an excellent outcome at discharge (GOS 5) and more than 90% a complete @entity2 clipping at the 6-month follow-up CT angiography although it was not statistically significant. CONCLUSION: Microsurgical clipping of the unruptured Acom @entity2 through a right-side surgical approach showed favorable postoperative clinical and anatomical outcomes, especially @entity2 smaller than 10mm.

title: Microsurgical efficacy and safety of a right-hemispheric approach for unruptured anterior communicating XXXX .

answer: @entity1


abstract: BACKGROUND: The role of an antireflux procedure in the management of @entity4 is controversial. To address this issue, we reviewed our experience with selective use of antireflux procedures in @entity0 with pure @entity4 ( @entity5 ; n = 26) and those with a partial sliding component (type III; n = 11). @entity0 AND METHODS: Surgical repair was performed on diagnosis in all 37 @entity0 . Competency of the lower esophageal sphincter was evaluated on the basis of reflux symptoms, and objectively, with endoscopy in 21 @entity0 and 24-hour esophageal pH studies in 17 @entity0 . Repair included an antireflux procedure in 11 @entity0 , as indicated by @entity3 . RESULTS: Preoperatively, 80% of both @entity1 @entity0 reported obstructive symptoms. @entity2 were present in 27% of @entity0 --19% of @entity5 and 45% of type III @entity0 . Endoscopy revealed @entity6 in 5 cases, and 24-hour pH studies indicated significant reflux in 3 of 17 @entity0 . There were no operative deaths and 1 recurrence. Symptoms improved in 92% of @entity0 after surgery. Medically manageable reflux was identified in 2 @entity0 . CONCLUSIONS: Frequent obstructive symptoms and the potential for @entity7 indicate elective repair of @entity4 on diagnosis. Significant @entity3 is less common, especially in @entity5 @entity0 , and excellent symptomatic results are obtained with selective application of an antireflux procedure.

title: Management of XXXX with a selective approach to antireflux surgery.

answer: @entity4


abstract: UNASSIGNED: Plants are constantly challenged by various abiotic stresses that negatively affect growth and productivity worldwide. During the course of their evolution, plants have developed sophisticated mechanisms to recognize external signals allowing them to respond appropriately to environmental conditions, although the degree of adjustability or tolerance to specific stresses differs from species to species. Overproduction of reactive @entity0 species (ROS; @entity3 , @entity7 ; @entity2 , [Formula: see text]; @entity6 radical, @entity4 (   ) and singlet @entity0 , @entity5 ) is enhanced under abiotic and/or biotic stresses, which can cause oxidative damage to plant macromolecules and cell structures, leading to inhibition of plant growth and development, or to @entity1 . Among the various ROS, freely diffusible and relatively long-lived @entity7 acts as a central player in stress signal transduction pathways. These pathways can then activate multiple acclamatory responses that reinforce resistance to various abiotic and biotic stressors. To utilize @entity7 as a signaling molecule, non-toxic levels must be maintained in a delicate balancing act between @entity7 production and scavenging. Several recent studies have demonstrated that the @entity7 -priming can enhance abiotic stress tolerance by modulating ROS detoxification and by regulating multiple stress-responsive pathways and gene expression. Despite the importance of the @entity7 -priming, little is known about how this process improves the tolerance of plants to stress. Understanding the mechanisms of @entity7 -priming-induced abiotic stress tolerance will be valuable for identifying biotechnological strategies to improve abiotic stress tolerance in crop plants. This review is an overview of our current knowledge of the possible mechanisms associated with @entity7 -induced abiotic oxidative stress tolerance in plants, with special reference to antioxidant metabolism.

title: XXXX priming modulates abiotic oxidative stress tolerance: insights from ROS detoxification and scavenging.

answer: @entity3


abstract: @entity5 induced by @entity8 30 micrograms.kg-1 was compared in 21 young (18-55 years) and 17 elderly (65-85 years) @entity0 . Anaesthesia was induced with @entity6 and maintained with @entity3 , @entity4 in @entity1 and @entity7 . @entity5 was measured electromyographically (Datex Relaxograph) at the adductor pollicis using train-of-four stimuli at 20 s intervals. The depth of maximum @entity5 was similar in young and elderly @entity0 (median 100% compared to 96%). However, the onset was significantly slower in the elderly: their mean (SD) time to 90% suppression of the first response of the train-of-four was 7.7 (1.8) min compared to 5.7 (1.7) min in the young (p = 0.002). Four min after @entity8 , the conditions for tracheal intubation were significantly poorer in the elderly (p < 0.001). Mean (SD) recovery of first response of the train-of-four to 25% of control was unaffected by age: young 79.0 (41.6) min; elderly 66.2 (32.1) min (p > 0.05). When the first response had reached 25% of control, @entity5 was antagonised with @entity2 60 micrograms.kg-1. The mean time to first response to 90% of control was similar in the young and the elderly @entity0 (9.1 min compared to 10.4 min). Recovery of the train-of-four ratio to 0.7 was significantly slower in the elderly: mean (SD) 17.1 (10.6) min compared to 10.1 (7.0) min (p = 0.03). @entity8 was associated with clinically insignificant haemodynamic changes in both groups.

title: The clinical pharmacology of XXXX in young adults and in elderly @entity0 .

answer: @entity8


abstract: @entity5 induced by @entity8 30 micrograms.kg-1 was compared in 21 young (18-55 years) and 17 elderly (65-85 years) @entity0 . Anaesthesia was induced with @entity6 and maintained with @entity3 , @entity4 in @entity1 and @entity7 . @entity5 was measured electromyographically (Datex Relaxograph) at the adductor pollicis using train-of-four stimuli at 20 s intervals. The depth of maximum @entity5 was similar in young and elderly @entity0 (median 100% compared to 96%). However, the onset was significantly slower in the elderly: their mean (SD) time to 90% suppression of the first response of the train-of-four was 7.7 (1.8) min compared to 5.7 (1.7) min in the young (p = 0.002). Four min after @entity8 , the conditions for tracheal intubation were significantly poorer in the elderly (p < 0.001). Mean (SD) recovery of first response of the train-of-four to 25% of control was unaffected by age: young 79.0 (41.6) min; elderly 66.2 (32.1) min (p > 0.05). When the first response had reached 25% of control, @entity5 was antagonised with @entity2 60 micrograms.kg-1. The mean time to first response to 90% of control was similar in the young and the elderly @entity0 (9.1 min compared to 10.4 min). Recovery of the train-of-four ratio to 0.7 was significantly slower in the elderly: mean (SD) 17.1 (10.6) min compared to 10.1 (7.0) min (p = 0.03). @entity8 was associated with clinically insignificant haemodynamic changes in both groups.

title: The clinical pharmacology of @entity8 in young adults and in elderly XXXX .

answer: @entity0


abstract: @entity5 is an @entity2 which affects one in 2500 live births. It is a multisystem disease and has a variety of presentations. The major clinical features affect the gastrointestinal and respiratory tracts. Severe @entity4 , @entity1 and @entity3 are common features of concern to anaesthetists. Improved care of young @entity0 has allowed many to survive into adulthood. Lung transplantation has significantly improved the outlook for many @entity0 . At Alfred Hospital, 74 @entity0 with @entity5 underwent 149 procedures from January 1978 to January 1994, with a mortality of 0.6% (95% CI 0.4%-0.8%). This retrospective cohort study describes the anaesthetic management and perioperative care of these @entity0 . Most of the anaesthetics were for procedures related to @entity5 but 12% were for unrelated conditions. @entity5 related procedures include diagnostic, venous access, enteral feeding procedures, treatment of complications of @entity5 and lung transplantation. Despite extremely poor respiratory function, these @entity0 can be managed with acceptably low postoperative mortality (1%). Pre- and postoperative care must be directed towards optimal clearance of viscous respiratory secretions. Procedures need to be planned so that optimal care can be given by each member of the team caring for @entity5 @entity0 .

title: Anaesthesia for adults with XXXX .

answer: @entity5


abstract: The mechanisms contributing to the @entity2 produced by nondepolarizing muscle relaxants and inhaled anesthetics include: 1) receptor blockade, 2) open or closed ion channel block, 3) decreased transmitter release, and 4) receptor desensitization. In this study we investigated the contributions of receptor and ion channel block. We used the two microelectrode voltage clamp to evaluate miniature end-plate currents (MEPCs) for amplitude and time constant of decay (tau) before and after the application of 1) @entity1 ( @entity4 ) (10(-7)-10(-6) M) alone, and then 2) the same concentration of @entity4 plus 0.5% or 1.0% @entity0 or @entity3 delivered by passing compressed air through a flow and temperature compensated vaporizer. The electrodes were maintained in the same cell for the entire experiment. @entity4 alone decreased MEPC amplitude to 91.3% +/- 4.5% and 65.1% +/- 5.6% of control at 10(-7) and 10(-6) M, respectively. MEPC amplitude with 10(-6) M @entity4 decreased further to 52.4% +/- 7.6% and 37.4% +/- 7.0% of control after the addition of 0.5% and 1.0% @entity0 , respectively. After the application of @entity4 10(-7) M tau was 94.7% +/- 3.1% of control and decreased to 73.7% +/- 7.1% of control with 10(-6) M @entity4 . After the application of @entity4 10(-6) M the addition of 0.5% and 1% @entity0 decreased tau to 52.4% +/- 7.6% and 30.0% +/- 5.9% of control. @entity3 produced similar changes. This study provides evidence that at least some of the augmentation of nondepolarizing relaxants by inhaled anesthetics can be explained by the additive effect of nondepolarizing muscle relaxants and inhaled anesthetics on MEPC amplitude and tau.

title: Some effects of XXXX alone and combined with @entity0 or @entity3 on neuromuscular transmission.

answer: @entity1


abstract: The mechanisms contributing to the @entity2 produced by nondepolarizing muscle relaxants and inhaled anesthetics include: 1) receptor blockade, 2) open or closed ion channel block, 3) decreased transmitter release, and 4) receptor desensitization. In this study we investigated the contributions of receptor and ion channel block. We used the two microelectrode voltage clamp to evaluate miniature end-plate currents (MEPCs) for amplitude and time constant of decay (tau) before and after the application of 1) @entity1 ( @entity4 ) (10(-7)-10(-6) M) alone, and then 2) the same concentration of @entity4 plus 0.5% or 1.0% @entity0 or @entity3 delivered by passing compressed air through a flow and temperature compensated vaporizer. The electrodes were maintained in the same cell for the entire experiment. @entity4 alone decreased MEPC amplitude to 91.3% +/- 4.5% and 65.1% +/- 5.6% of control at 10(-7) and 10(-6) M, respectively. MEPC amplitude with 10(-6) M @entity4 decreased further to 52.4% +/- 7.6% and 37.4% +/- 7.0% of control after the addition of 0.5% and 1.0% @entity0 , respectively. After the application of @entity4 10(-7) M tau was 94.7% +/- 3.1% of control and decreased to 73.7% +/- 7.1% of control with 10(-6) M @entity4 . After the application of @entity4 10(-6) M the addition of 0.5% and 1% @entity0 decreased tau to 52.4% +/- 7.6% and 30.0% +/- 5.9% of control. @entity3 produced similar changes. This study provides evidence that at least some of the augmentation of nondepolarizing relaxants by inhaled anesthetics can be explained by the additive effect of nondepolarizing muscle relaxants and inhaled anesthetics on MEPC amplitude and tau.

title: Some effects of @entity1 alone and combined with @entity0 or XXXX on neuromuscular transmission.

answer: @entity3


abstract: The mechanisms contributing to the @entity2 produced by nondepolarizing muscle relaxants and inhaled anesthetics include: 1) receptor blockade, 2) open or closed ion channel block, 3) decreased transmitter release, and 4) receptor desensitization. In this study we investigated the contributions of receptor and ion channel block. We used the two microelectrode voltage clamp to evaluate miniature end-plate currents (MEPCs) for amplitude and time constant of decay (tau) before and after the application of 1) @entity1 ( @entity4 ) (10(-7)-10(-6) M) alone, and then 2) the same concentration of @entity4 plus 0.5% or 1.0% @entity0 or @entity3 delivered by passing compressed air through a flow and temperature compensated vaporizer. The electrodes were maintained in the same cell for the entire experiment. @entity4 alone decreased MEPC amplitude to 91.3% +/- 4.5% and 65.1% +/- 5.6% of control at 10(-7) and 10(-6) M, respectively. MEPC amplitude with 10(-6) M @entity4 decreased further to 52.4% +/- 7.6% and 37.4% +/- 7.0% of control after the addition of 0.5% and 1.0% @entity0 , respectively. After the application of @entity4 10(-7) M tau was 94.7% +/- 3.1% of control and decreased to 73.7% +/- 7.1% of control with 10(-6) M @entity4 . After the application of @entity4 10(-6) M the addition of 0.5% and 1% @entity0 decreased tau to 52.4% +/- 7.6% and 30.0% +/- 5.9% of control. @entity3 produced similar changes. This study provides evidence that at least some of the augmentation of nondepolarizing relaxants by inhaled anesthetics can be explained by the additive effect of nondepolarizing muscle relaxants and inhaled anesthetics on MEPC amplitude and tau.

title: Some effects of @entity1 alone and combined with XXXX or @entity3 on neuromuscular transmission.

answer: @entity0


abstract: UNASSIGNED: Anti- @entity13 receptor (anti-NMDAR) @entity6 is a severe but @entity4 , initially identified in young @entity0 with an @entity2 . Symptoms include mood, behavior and personality irregularities that resemble acute @entity9 . The present study reports the rare case of a patient with anti-NMDAR @entity6 and severe @entity1 , that exhibited a rapid recovery following a laparoscopic salpingo-oophorectomy. The 39-year-old @entity0 was admitted to the Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine (Osaka, Japan) with a 5-day history of fever and @entity5 . One week later, the @entity0 developed @entity11 and @entity12 . Initially, a diagnosis of limbic or herpes @entity6 was considered; thus, the @entity0 was administered @entity10 and received @entity8 pulse therapy. However, the @entity0 subsequently developed @entity7 , and in response, a tracheal intubation, mechanical ventilation and plasmapheresis were performed. Anti-NMDAR @entity6 was subsequently considered as a diagnosis and mediastinal and pelvic computed tomography (CT) examinations were conducted to detect for the presence of a @entity3 . A 24*24-mm cystic lesion was identified in the pelvis from an abdominal CT scan and the lesion appeared to be an @entity2 . In addition, serum and cerebrospinal fluid samples were collected, and were found to test positive for anti-NMDAR antibodies. A laparoscopic salpingo-oophorectomy was performed, which resulted in rapid improvement of the @entity0 mental symptoms, followed by a complete recovery.

title: Complete recovery from paraneoplastic anti-NMDAR XXXX associated with a small @entity2 following a laparoscopic salpingo-oophorectomy: A case report.

answer: @entity6


abstract: UNASSIGNED: Anti- @entity13 receptor (anti-NMDAR) @entity6 is a severe but @entity4 , initially identified in young @entity0 with an @entity2 . Symptoms include mood, behavior and personality irregularities that resemble acute @entity9 . The present study reports the rare case of a patient with anti-NMDAR @entity6 and severe @entity1 , that exhibited a rapid recovery following a laparoscopic salpingo-oophorectomy. The 39-year-old @entity0 was admitted to the Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine (Osaka, Japan) with a 5-day history of fever and @entity5 . One week later, the @entity0 developed @entity11 and @entity12 . Initially, a diagnosis of limbic or herpes @entity6 was considered; thus, the @entity0 was administered @entity10 and received @entity8 pulse therapy. However, the @entity0 subsequently developed @entity7 , and in response, a tracheal intubation, mechanical ventilation and plasmapheresis were performed. Anti-NMDAR @entity6 was subsequently considered as a diagnosis and mediastinal and pelvic computed tomography (CT) examinations were conducted to detect for the presence of a @entity3 . A 24*24-mm cystic lesion was identified in the pelvis from an abdominal CT scan and the lesion appeared to be an @entity2 . In addition, serum and cerebrospinal fluid samples were collected, and were found to test positive for anti-NMDAR antibodies. A laparoscopic salpingo-oophorectomy was performed, which resulted in rapid improvement of the @entity0 mental symptoms, followed by a complete recovery.

title: Complete recovery from paraneoplastic anti-NMDAR @entity6 associated with a small XXXX following a laparoscopic salpingo-oophorectomy: A case report.

answer: @entity2


abstract: STUDY OBJECTIVE: To develop criteria that optimize clinical decisionmaking in the use of radiography after isolated knee @entity1 in adults. DESIGN: A prospective survey of emergency department @entity0 over a 7-month period. Standardized data forms were completed by emergency physicians, residents, and certified physician assistants. SETTING: A large suburban community teaching hospital. @entity0 : Two hundred forty-two @entity0 older than 17 years with isolated @entity4 sustained less than 24 hours previously. RESULTS: We constructed a clinical decision model, calculating sensitivity, specificity, and odds ratios. Twenty-eight @entity0 (11.6%) had @entity2 , with the patella the most commonly fractured osseous structure. @entity0 able to walk without limping had not experienced a @entity2 , nor had @entity0 with twist injuries without effusion. Sensitivity of this model for detecting @entity2 was 1.0 (99% confidence interval, .97 to 1.0), and specificity was .337 (99% confidence interval, .26 to .42). CONCLUSION: Clinical decision rules are effective in detecting knee @entity2 with 100% sensitivity and with sufficient specificity to eliminate 29% of knee radiographs in the @entity3 . These findings require prospective validation.

title: Clinical decision rules discriminate between XXXX and nonfractures in acute isolated knee @entity1 .

answer: @entity2


abstract: STUDY OBJECTIVE: To develop criteria that optimize clinical decisionmaking in the use of radiography after isolated knee @entity1 in adults. DESIGN: A prospective survey of emergency department @entity0 over a 7-month period. Standardized data forms were completed by emergency physicians, residents, and certified physician assistants. SETTING: A large suburban community teaching hospital. @entity0 : Two hundred forty-two @entity0 older than 17 years with isolated @entity4 sustained less than 24 hours previously. RESULTS: We constructed a clinical decision model, calculating sensitivity, specificity, and odds ratios. Twenty-eight @entity0 (11.6%) had @entity2 , with the patella the most commonly fractured osseous structure. @entity0 able to walk without limping had not experienced a @entity2 , nor had @entity0 with twist injuries without effusion. Sensitivity of this model for detecting @entity2 was 1.0 (99% confidence interval, .97 to 1.0), and specificity was .337 (99% confidence interval, .26 to .42). CONCLUSION: Clinical decision rules are effective in detecting knee @entity2 with 100% sensitivity and with sufficient specificity to eliminate 29% of knee radiographs in the @entity3 . These findings require prospective validation.

title: Clinical decision rules discriminate between @entity2 and nonfractures in acute isolated knee XXXX .

answer: @entity1


abstract: Forty-six @entity0 with previously untreated, advanced @entity2 received @entity9 ( @entity11 , @entity9 ) and @entity10 (CLB) to assess the efficacy and @entity3 of this combination. @entity9 300 mg m-2 was given on day 1 with CLB 10 mg daily for 7, 10 or 14 days; 6 treatment courses were given at 4-6 weekly intervals in the absence of disease progression. @entity1 response was assessed, where possible, by restaging laparotomy after 6 treatment cycles. Five complete and 16 partial remission were seen in 37 evaluable @entity0 giving an overall response rate of 57%. The median survival of all @entity0 was 15 months. The major @entity3 was myelosuppression. @entity4 and @entity5 were generally minor (WHO, grades I or II) and most courses were given on an outpatient basis. @entity8 was the major factor causing treatment delays, particularly with the 10 and 14 day CLB regimens. @entity6 was minimal in the early chemotherapy cycles but the data suggest that cumulative @entity3 may occur. This combination may provide a satisfactory degree of efficacy with less @entity3 than @entity7 -based regimens.

title: A pilot study of @entity9 ( XXXX , @entity9 ) and @entity10 in combination for advanced @entity2 .

answer: @entity11


abstract: Forty-six @entity0 with previously untreated, advanced @entity2 received @entity9 ( @entity11 , @entity9 ) and @entity10 (CLB) to assess the efficacy and @entity3 of this combination. @entity9 300 mg m-2 was given on day 1 with CLB 10 mg daily for 7, 10 or 14 days; 6 treatment courses were given at 4-6 weekly intervals in the absence of disease progression. @entity1 response was assessed, where possible, by restaging laparotomy after 6 treatment cycles. Five complete and 16 partial remission were seen in 37 evaluable @entity0 giving an overall response rate of 57%. The median survival of all @entity0 was 15 months. The major @entity3 was myelosuppression. @entity4 and @entity5 were generally minor (WHO, grades I or II) and most courses were given on an outpatient basis. @entity8 was the major factor causing treatment delays, particularly with the 10 and 14 day CLB regimens. @entity6 was minimal in the early chemotherapy cycles but the data suggest that cumulative @entity3 may occur. This combination may provide a satisfactory degree of efficacy with less @entity3 than @entity7 -based regimens.

title: A pilot study of XXXX ( @entity11 , @entity9 ) and @entity10 in combination for advanced @entity2 .

answer: @entity9


abstract: Forty-six @entity0 with previously untreated, advanced @entity2 received @entity9 ( @entity11 , @entity9 ) and @entity10 (CLB) to assess the efficacy and @entity3 of this combination. @entity9 300 mg m-2 was given on day 1 with CLB 10 mg daily for 7, 10 or 14 days; 6 treatment courses were given at 4-6 weekly intervals in the absence of disease progression. @entity1 response was assessed, where possible, by restaging laparotomy after 6 treatment cycles. Five complete and 16 partial remission were seen in 37 evaluable @entity0 giving an overall response rate of 57%. The median survival of all @entity0 was 15 months. The major @entity3 was myelosuppression. @entity4 and @entity5 were generally minor (WHO, grades I or II) and most courses were given on an outpatient basis. @entity8 was the major factor causing treatment delays, particularly with the 10 and 14 day CLB regimens. @entity6 was minimal in the early chemotherapy cycles but the data suggest that cumulative @entity3 may occur. This combination may provide a satisfactory degree of efficacy with less @entity3 than @entity7 -based regimens.

title: A pilot study of @entity9 ( @entity11 , XXXX ) and @entity10 in combination for advanced @entity2 .

answer: @entity9


abstract: Forty-six @entity0 with previously untreated, advanced @entity2 received @entity9 ( @entity11 , @entity9 ) and @entity10 (CLB) to assess the efficacy and @entity3 of this combination. @entity9 300 mg m-2 was given on day 1 with CLB 10 mg daily for 7, 10 or 14 days; 6 treatment courses were given at 4-6 weekly intervals in the absence of disease progression. @entity1 response was assessed, where possible, by restaging laparotomy after 6 treatment cycles. Five complete and 16 partial remission were seen in 37 evaluable @entity0 giving an overall response rate of 57%. The median survival of all @entity0 was 15 months. The major @entity3 was myelosuppression. @entity4 and @entity5 were generally minor (WHO, grades I or II) and most courses were given on an outpatient basis. @entity8 was the major factor causing treatment delays, particularly with the 10 and 14 day CLB regimens. @entity6 was minimal in the early chemotherapy cycles but the data suggest that cumulative @entity3 may occur. This combination may provide a satisfactory degree of efficacy with less @entity3 than @entity7 -based regimens.

title: A pilot study of @entity9 ( @entity11 , @entity9 ) and XXXX in combination for advanced @entity2 .

answer: @entity10


abstract: Forty-six @entity0 with previously untreated, advanced @entity2 received @entity9 ( @entity11 , @entity9 ) and @entity10 (CLB) to assess the efficacy and @entity3 of this combination. @entity9 300 mg m-2 was given on day 1 with CLB 10 mg daily for 7, 10 or 14 days; 6 treatment courses were given at 4-6 weekly intervals in the absence of disease progression. @entity1 response was assessed, where possible, by restaging laparotomy after 6 treatment cycles. Five complete and 16 partial remission were seen in 37 evaluable @entity0 giving an overall response rate of 57%. The median survival of all @entity0 was 15 months. The major @entity3 was myelosuppression. @entity4 and @entity5 were generally minor (WHO, grades I or II) and most courses were given on an outpatient basis. @entity8 was the major factor causing treatment delays, particularly with the 10 and 14 day CLB regimens. @entity6 was minimal in the early chemotherapy cycles but the data suggest that cumulative @entity3 may occur. This combination may provide a satisfactory degree of efficacy with less @entity3 than @entity7 -based regimens.

title: A pilot study of @entity9 ( @entity11 , @entity9 ) and @entity10 in combination for advanced XXXX .

answer: @entity2


abstract: AIM: This metaanalysis was performed to evaluate the prevalence of the radiological assessed @entity2 in the whole community. MATERIALS AND METHODS: Medical databases (Medline, EMBASE, Cochrane) were searched for the strategy: [" @entity1 " and "Knee" and "Prevalence"]. The deadline for the search was 31.12.2009. Two investigators (first and senior author) independently made the selection from 17 studies (from a total of 1428) according to the inclusion criteria: a cross-sectional study of the whole community, radiological investigation and definition of knee ROA by an established radiological score. Only studies in English or German language were evaluated. Effect sizes (event rate, odds ratio [OR] and confidence interval [CI]) were calculated by the software "Comprehensive Metaanalysis V2". Study heterogeneity (I2) was determined accordingly to Higgins. RESULTS: The kappa index for interobserver validity was k = 0.948. All studies judged the grade of @entity1 according to the Kellgren-Lawrence (KL) score. For calculation of knee ROA KL grades 2+ were estimated only. The total prevalence of knee ROA was 24.3 % (CI 23.4-25.2 %). The whole prevalence in male @entity0 was 24.3 % (CI 23.4-25.2 %); I2 = 59.4 (p = 0.002) and in female @entity0 32.6 % (CI 31.8-33.4 %); I2 = 49,1 (p < 0.001). Younger male @entity0 (age 50-) had a prevalence of 5.6 (CI 4.5-6.8). In older @entity0 (80+) the male prevalence was 44.5 % (CI 39.6-49.5 %). In this age group female @entity0 had a prevalence of 71.6 % (CI 67.6-75.3 %). The higher prevalence of knee ROA in female @entity0 was significant (OR = 1.8 [1.7-1.9]; I2 = 46.0 [p < 0.001]). The prevalence of knee ROA was higher in male Asians compared with male Caucasians (OR = 1.1, CI 0.9-1.2; p = 0.080) in tendency. This difference was significant in female @entity0 (OR = 2.2; CI 2.0-2.4; p < 0.001). Furthermore another trend was evaluated. Female @entity0 (70-79 years) from the birth-year cohort 1920- had a prevalence of 37.8 % (CI 35.9-39.7)%. In contrast female @entity0 from the birth-year cohort 1920 had a prevalence of 62.8 % (CI 60.8-64.8 %) at 70-79 years. This difference was significant (OR = 2.8; CI 2.5-3.1; p < 0.001). CONCLUSIONS: This investigation confirms the high prevalence of knee ROA. The evaluated data may serve as a reference for medical or scientific investigations in the future.

title: [The prevalence of radiological XXXX in relation to age, gender, birth-year cohort, and ethnic origins].

answer: @entity1